5200 Illumina Way
905 articles with Illumina, Inc.
Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics
Illumina, Inc. (NASDAQ: ILMN), today announced that on September 30, its Illumina Genomics Forum (IGF) will feature Bill Gates, co-chair of the Bill & Melinda Gates Foundation, who will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health.
Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0, its most accurate and comprehensive secondary analysis platform.
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2022 following the close of market on Thursday, August 11, 2022.
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative.
Illumina, Inc. announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health.
Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of a research test, codeveloped with Merck.
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced Joydeep Goswami, Chief Strategy and Corporate Development Officer, will also serve as interim Chief Financial Officer while the company conducts a search for a permanent CFO.
Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, shared key customer-focused announcements and presentations it will make at the Advances in Genome Biology and Technology General Meeting, taking place June 6–9 in Orlando, Fla.
Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7 in Chicago.
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the addition of a companion diagnostic indication to its CE-marked in vitro diagnostic TruSight™ Oncology Comprehensive test.
Illumina and Deerfield Management have entered into a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies.
Illumina, Inc. announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs.
Illumina, Inc. announced its financial results for the first quarter of fiscal year 2022, which include consolidated financial results for GRAIL.
Illumina, Inc. announced that its executives will be speaking at the following investor conference:.
Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children
Illumina, Inc. announced an agreement with Germany's Hannover Medical School to implement the use of whole-genome sequencing in critically ill children suspected of having a genetic or rare disease.
Illumina, Inc. (NASDAQ: ILMN) today announced that it will issue results for the first quarter 2022 following the close of market on Thursday, May 5, 2022.
BMS filed a patent infringement lawsuit against AstraZeneca over Imfinzi, while Guardant Health issued a statement in response to Illumina's intellectual property lawsuit.
Guardant Health, Inc. today provided the following statement regarding a lawsuit filed by Illumina that seeks to challenge Guardant Health’s ownership and authorship of a portion of its intellectual property and to suppress competition in the market.
Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications
Illumina, Inc. (NASDAQ: ILMN) has invested in seven new genomics companies to join the fourth global funding cycle of Illumina Accelerator San Francisco Bay Area and Cambridge, UK.
Illumina, Inc. announced the launch of TruSight™ Oncology Comprehensive, a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.